Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Andrea S. Bauer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7919-0497; OpenAlex author ID A5082559565. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 19

  1. Blood-based prediction and early detection of pancreatic cancer recurrence after tumor resection Co-author DOI 10.20892/j.issn.2095-3941.2025.0495↗
  2. Genome-Wide CRISPR Screen Identifies Genes Involved in Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16213684↗
  3. DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma. Co-author DOI 10.1136/gutjnl-2023-330155↗
  4. Blood biomarkers for differential diagnosis and early detection of pancreatic cancer. Co-author DOI 10.1016/j.ctrv.2021.102193↗
  5. Promoter Hypermethylation Promotes the Binding of Transcription Factor NFATc1, Triggering Oncogenic Gene Activation in Pancreatic Cancer. Co-author DOI 10.3390/cancers13184569↗
  6. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis. Last author DOI 10.1002/1878-0261.12684↗
  7. Novel Autoantibody Signatures in Sera of Patients with Pancreatic Cancer, Chronic Pancreatitis and Autoimmune Pancreatitis: A Protein Microarray Profiling Appr… Co-author DOI 10.3390/ijms21072403↗
  8. Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. Co-author DOI 10.1002/ijc.31087↗
  9. Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer. Co-author DOI 10.18632/oncotarget.24312↗
  10. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Co-author DOI 10.1053/j.gastro.2016.08.040↗
  11. Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-15-0390↗
  12. Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. Co-author DOI 10.15252/emmm.201404837↗
  13. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. Co-author DOI 10.1038/onc.2013.312↗
  14. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗
  15. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.3892/or.2013.2285↗
  16. Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines. Co-author DOI 10.1016/j.jprot.2012.04.042↗
  17. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. Co-author DOI 10.1371/journal.pone.0034151↗
  18. Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). First author DOI 10.1111/j.1476-5381.2010.01125.x↗
  19. Pancreatic cancer susceptibility loci and their role in survival. Co-author DOI 10.1371/journal.pone.0027921↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jörg D. Hoheisel · 18 shared papers, 2011–2026 · strength 1.50
  2. Thilo Hackert · 9 shared papers, 2016–2026 · strength 1.02
  3. Markus Wolfgang Büchler · 10 shared papers, 2011–2026 · strength 0.91
  4. Nathalia A. Giese · 12 shared papers, 2011–2023 · strength 0.87
  5. Fawaz N. Al-Shaheri · 3 shared papers, 2021–2026 · strength 0.56
  6. Oliver Strobel · 7 shared papers, 2015–2020 · strength 0.47
  7. Mohamed Saiel Saeed Alhamdani · 3 shared papers, 2012–2026 · strength 0.43
  8. Yenan Wu · 3 shared papers, 2020–2023 · strength 0.40
  9. Mehdi Manoochehri · 2 shared papers, 2020–2023 · strength 0.27
  10. John P. Neoptolemos · 7 shared papers, 2011–2018 · strength 0.25
  11. Miriam Schenk · 1 shared paper, 2026 · strength 0.25
  12. Ulrike Heger · 1 shared paper, 2026 · strength 0.25
  13. William Greenhalf · 6 shared papers, 2011–2018 · strength 0.23
  14. Eithne Costello · 6 shared papers, 2011–2018 · strength 0.23
  15. Risky Oktriani · 1 shared paper, 2024 · strength 0.22
  16. Haoqi Du · 1 shared paper, 2024 · strength 0.22
  17. Michael Boettcher · 1 shared paper, 2024 · strength 0.22
  18. Klaus Felix · 2 shared papers, 2018–2020 · strength 0.17
  19. Matthias M. Gaida · 3 shared papers, 2015–2018 · strength 0.16
  20. Aldo Scarpa · 3 shared papers, 2016–2018 · strength 0.15
  21. Jens Werner · 5 shared papers, 2011–2015 · strength 0.14
  22. Sahar Ghassem‐Zadeh · 1 shared paper, 2020 · strength 0.10
  23. M. Neulinger · 1 shared paper, 2020 · strength 0.10
  24. Jean‐Louis Frossard · 1 shared paper, 2020 · strength 0.10
  25. Masaru Yoshida · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.